<DOC>
	<DOCNO>NCT00739986</DOCNO>
	<brief_summary>Assessment number day ' treatment semapimod necessary efficacy , measure response rate CNI-1493 compare placebo , patient moderate severe Crohn 's disease ( CD ) .</brief_summary>
	<brief_title>Semapimod Treatment Moderate Severe Crohn 's Disease 1 3 Days ' Treatment Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Semapimod</mesh_term>
	<criteria>1 . Men woman least 18 year age . 2 . Baseline Crohn 's Disease Activity Index ( CDAI ) 250400 . 3 . Crohn 's disease least 3 month duration , colitis , ileitis , ileocolitis , confirm radiography and/or endoscopy . 4 . Those childbearing potential use barrier method ( diaphragm condom ) contraception continue least 3 month last study medication . It recommend two form use . 5 . Patients receive medication CD medication least 8 week prior screen stable dos least 2 week prior screen , follow exception : methotrexate stable dose least 4 week receive 25 mg/wk azathioprine 6mercaptopurine stable dose least 10 week steroids steroid least 2 week stable dose 2 week . They receive 20 mg/day prednisone equivalent mesalazine least 6 week stable dose least 2 week antibiotics CD least 2 week stable dose 2 week 6 . Any CD medication discontinue discontinue least 4 week prior screen , exception infliximab , discontinue least 8 week prior screen . 7 . The screening laboratory test meet follow criterion : Hgb &gt; = 8.5 g/dL ( 5.3 mmol/L ) WBC 3.520 x 109/L Neutrophils &gt; = 1.5 x 109/L Platelets &gt; = 100 x 109/L ALT ( SGPT ) &lt; 1.5 x upper limit normal range Alkaline phosphatase &lt; 2.5 x upper limit normal range Bilirubin &lt; 25 mmol/L ( 1.5 mg/dl ) Creatinine &lt; 110 mol/L ( 1.2 mg/dl ) 8 . Patients able adhere study visit schedule and/or protocol requirement . 9 . Patients able give inform consent consent obtain prior study specific screening procedure . 1 . Treatment experimental therapeutic within last 4 week enrolment . 2 . History tuberculosis , either clinically evidence positive chest xray ( exclusion criterion # 8 ) PPD . 3 . Patients receive antiTNF therapy , infliximab , within 8 week screen study . Patients receive antiTNF therapy &gt; 8 week prior screen eligible . 4 . Patients ostomy , extensive bowel resection ( e.g. , 100cm small bowel , proctocolectomy colectomy ileorectal anastomosis ) . Segmental colectomy permit . 5 . Patients immediately need surgery active gastrointestinal bleeding , peritonitis , intestinal obstruction , intraabdominal pancreatic abscess require surgical drainage . 6 . Patients know severe fix symptomatic stenosis small large intestine . 7 . Evidence time enrolment bowel obstruction history within precede six month confirm radiography , endoscopy , surgery . 8 . Patients clinically significant abnormality granuloma evidence primary tuberculosis infection chest Xray 9 . Patients current sign symptom clinically significant hematologic , endocrine , pulmonary , cardiac , neurologic cerebral disease . 10 . Patients previous diagnosis , know , malignancy . 11 . Patients serious infection , hepatitis , HIV , pneumonia pyelonephritis , within 3 month prior screen . 12 . History opportunistic infection herpes zoster within 2 month prior screen , evidence active CMV , active Pneumocystis carinii , drug resistant atypical mycobacterium . 13 . Patients stool examination positive enteric pathogen , pathogenic ovum parasite , Clostridium difficile toxin . 14 . Women pregnant breastfeeding . 15 . A psychiatric , addictive , disorder compromise ability give truly informed consent participation study . 16 . Patients receive CNI1493 past . 17 . More three dos NSAIDs , include aspirin COX2 inhibitor , within two week prior start study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>TNF-alpha</keyword>
	<keyword>IL-6</keyword>
	<keyword>MAP Kinase</keyword>
	<keyword>CNI-1493</keyword>
</DOC>